Compare NATL & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | TARS |
|---|---|---|
| Founded | 2023 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | NATL | TARS |
|---|---|---|
| Price | $37.74 | $80.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $42.75 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 446.1K | 376.9K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $4,322,000,000.00 | $366,100,000.00 |
| Revenue This Year | $2.83 | $147.24 |
| Revenue Next Year | $3.96 | $53.11 |
| P/E Ratio | $21.33 | ★ N/A |
| Revenue Growth | 0.63 | ★ 182.44 |
| 52 Week Low | $22.30 | $38.51 |
| 52 Week High | $42.23 | $85.25 |
| Indicator | NATL | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 57.85 | 61.12 |
| Support Level | $36.12 | $77.44 |
| Resistance Level | $37.61 | $85.25 |
| Average True Range (ATR) | 1.02 | 3.56 |
| MACD | 0.21 | -0.27 |
| Stochastic Oscillator | 95.11 | 62.69 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.